| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology and Clinical Research Center (Drs. Ma, Nishimura, Ohta, Saida), Utano National Hospital, Kyoto; Kyoto Red Cross Blood Center (Drs. Mine and Saji); Kyoto Microbiological Institute (Dr. Obayashi); Department of Pediatrics (Dr. Kuroki), Kobe City General Hospital, Public Health Research Institute of Kobe City (Dr. Nukina); Third Department of Internal Medicine (Dr. Kawakami), Hiroshima University School of Medicine, Hiroshima; and Virus Research Institute (Dr. Uchiyama), Kyoto University, Kyoto, Japan.
Address correspondence and reprint requests to Dr. M. Nishimura, Department of Neurology and Clinical Research Center, Utano National Hospital, Ukyo-ku, Kyoto 616, Japan.
Objective: We examined a possible involvement of genetic factors influencing the development of Guillain-Barré syndrome (GBS).
Methods: We studied T-cell receptor (TCR), alpha-chain constant (AC), and beta-chain variable (BV) gene polymorphisms using microsatellite markers and serologic HLA class I antigens, HLA-DRB1, and HLA-DQB1 alleles in 81 Japanese patients with GBS and 87 controls.
Results: There were no significant differences in these genetic markers between GBS patients and controls. Subgrouping of GBS patients according to recent Campylobacter jejuni infection, the presence of anti-GM1 antibody in the sera, or their combinations also failed to reveal significant associations with these genetic markers. There was, however, a tendency for an increased frequency of HLA-DRB1*0803 in the C. jejuni + GM1 + GBS group, when compared with controls.
Conclusions: The data suggest that the roles of TCRAC, T-cell receptor beta-chain variable (TCRBV), HLA class I or class II in the development of GBS are not critical, and further research is necessary to clarify other genes encoded within the HLA region for genetic susceptibility to GBS.
Received December 15, 1997. Accepted in final form March 17, 1998.
This article has been cited by other articles:
|
|
 |
|
  K. Kaida, T. Ariga, and R. K Yu Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A review Glycobiology, July 1, 2009; 19(7): 676 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Janssen, K. A. Krogfelt, S. A. Cawthraw, W. van Pelt, J. A. Wagenaar, and R. J. Owen Host-Pathogen Interactions in Campylobacter Infections: the Host Perspective Clin. Microbiol. Rev., July 1, 2008; 21(3): 505 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Yu, S. Usuki, and T. Ariga Ganglioside Molecular Mimicry and Its Pathological Roles in Guillain-Barre Syndrome and Related Diseases Infect. Immun., December 1, 2006; 74(12): 6517 - 6527. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Geleijns, G. M.Th. Schreuder, B. C. Jacobs, K. Sintnicolaas, R. van Koningsveld, J. Meulstee, J. D. Laman, and P. A. van Doorn HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome Neurology, January 11, 2005; 64(1): 44 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Prendergast and A. P. Moran Review: Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies Innate Immunity, October 1, 2000; 6(5): 341 - 359. [Abstract] [PDF]
|
|
|
|
 |
|
 A. K. Asbury New Concepts of Guillain-Barre Syndrome J Child Neurol, March 1, 2000; 15(3): 183 - 191. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
